Journal
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Volume 42, Issue 8, Pages 900-913Publisher
WILEY
DOI: 10.1111/j.1365-2362.2012.02667.x
Keywords
Emphysema; lung injury; mesenchymal stem cell; pulmonary hypertension; regenerative medicine; stem cell
Funding
- NIH [HL092868, HL102897, HL108801, HL085446, HL055454, HL107192, HL61795, HL70819, HL48743, HL108630]
Ask authors/readers for more resources
Eur J Clin Invest 2012 Abstract Background Chronic lung diseases contribute significantly to the morbidity and mortality of the population. There are few effective treatments for many chronic lung diseases, and even fewer therapies that can arrest or reverse the progress of the disease. Design In this review, we present the current state of regenerative therapies for the treatment of chronic lung diseases. We focus on endothelial progenitor cells, mesenchymal stem cells, and endogenous lung stem/progenitor cells; summarize the work to date in models of lung diseases for each of these therapies; and consider their potential benefits and risks as viable therapies for patients with lung diseases. Conclusions Cell-based regenerative therapies for lung diseases offer great promise, with preclinical studies suggesting that the next decade should provide the evidence necessary for their ultimate application to our therapeutic armamentarium.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available